AR057849A1 - Dialurrea para el tratamiento de hipertension pulmonar - Google Patents
Dialurrea para el tratamiento de hipertension pulmonarInfo
- Publication number
- AR057849A1 AR057849A1 ARP060104767A ARP060104767A AR057849A1 AR 057849 A1 AR057849 A1 AR 057849A1 AR P060104767 A ARP060104767 A AR P060104767A AR P060104767 A ARP060104767 A AR P060104767A AR 057849 A1 AR057849 A1 AR 057849A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- formula
- treatment
- combination
- pulmonary hypertension
- Prior art date
Links
- 208000002815 pulmonary hypertension Diseases 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 4
- 229940124597 therapeutic agent Drugs 0.000 abstract 3
- -1 4-chloro-3-trifluoromethylphenyl Chemical group 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 1
- 229940122858 Elastase inhibitor Drugs 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 229940127219 anticoagulant drug Drugs 0.000 abstract 1
- 239000003524 antilipemic agent Substances 0.000 abstract 1
- 230000004872 arterial blood pressure Effects 0.000 abstract 1
- 239000000480 calcium channel blocker Substances 0.000 abstract 1
- 229940097217 cardiac glycoside Drugs 0.000 abstract 1
- 239000002368 cardiac glycoside Substances 0.000 abstract 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 229940030606 diuretics Drugs 0.000 abstract 1
- 239000003602 elastase inhibitor Substances 0.000 abstract 1
- 230000003511 endothelial effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 abstract 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003815 prostacyclins Chemical class 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229930002534 steroid glycoside Natural products 0.000 abstract 1
- 150000008143 steroidal glycosides Chemical class 0.000 abstract 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 abstract 1
- 229940124549 vasodilator Drugs 0.000 abstract 1
- 239000003071 vasodilator agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente se refiere a composiciones farmacéuticas para el tratamiento, prevencion o control de hipertension pulmonar que comprenden metilamida del ácido 4{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridina-2-carboxílico, opcionalmente combinada con al menos un agente terapéutico adicional. Reivindicacion 1: Uso de un compuesto de formula (1) o una sal farmacéuticamente aceptable, polimorfo, solvato, hidrato, metabolito, profármaco o forma diastereoisomérica del mismo para la fabricacion de un medicamento para el tratamiento, prevencion o control de hipertension pulmonar, en el que dicho compuesto es de formula (1). Reivindicacion 2: Combinacion que comprende al menos un compuesto de formula (1) como se define en la reivindicacion 1 y al menos un inhibidor de elastasa y/o un inhibidor de cinasa. Reivindicacion 4: Combinacion que comprende al menos un compuesto de formula (1) como se define en la reivindicacion 1 o una combinacion como se define en cualquiera de las reivindicaciones 2 a 3 y al menos un agente terapéutico seleccionado del grupo constituido por anticoagulantes, diuréticos, glucosidos cardíacos, bloqueantes de los canales de calcio, vasodilatadores, análogos de la prostaciclina, antagonistas del endotelio, inhibidores de fosfodiesterasa, inhibidores de endopeptidasa, agentes hipolipemiantes, inhibidores del tromboxano y otros agentes terapéuticos conocidos para reducir la presion arterial pulmonar.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05024509 | 2005-11-10 | ||
| EP05027450 | 2005-12-15 | ||
| EP06012234 | 2006-06-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR057849A1 true AR057849A1 (es) | 2007-12-19 |
Family
ID=37622057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060104767A AR057849A1 (es) | 2005-11-10 | 2006-10-31 | Dialurrea para el tratamiento de hipertension pulmonar |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20100035888A1 (es) |
| EP (1) | EP1948170A1 (es) |
| JP (1) | JP5084736B2 (es) |
| KR (1) | KR20080067000A (es) |
| AR (1) | AR057849A1 (es) |
| AU (1) | AU2006312714A1 (es) |
| BR (1) | BRPI0618522A2 (es) |
| CA (1) | CA2628849A1 (es) |
| CR (1) | CR9953A (es) |
| EC (1) | ECSP088430A (es) |
| GT (1) | GT200800058A (es) |
| IL (1) | IL191178A0 (es) |
| NO (1) | NO20082498L (es) |
| PE (1) | PE20070806A1 (es) |
| SV (1) | SV2009002900A (es) |
| TW (1) | TW200733961A (es) |
| UY (1) | UY29903A1 (es) |
| WO (1) | WO2007054216A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2377847T3 (es) * | 1999-01-13 | 2012-04-02 | Bayer Healthcare Llc | Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38 |
| US8124630B2 (en) * | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US7371763B2 (en) * | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| US20080108672A1 (en) * | 2002-01-11 | 2008-05-08 | Bernd Riedl | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
| EP1478358B1 (en) | 2002-02-11 | 2013-07-03 | Bayer HealthCare LLC | Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis |
| NZ562413A (en) * | 2003-02-21 | 2009-02-28 | Resmed Ltd | Headgear assembly for nasal pillows mask |
| US7557129B2 (en) * | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| ES2288694T3 (es) * | 2003-05-20 | 2008-01-16 | Bayer Pharmaceuticals Corporation | Diaril ureas para enfermedades mediadas por el receptor del factor de crecimiento derivado de plaquetas. |
| KR101139557B1 (ko) | 2003-07-23 | 2012-04-30 | 바이엘 파마슈티칼스 코포레이션 | 질환 및 상태의 치료 및 예방을 위한 플루오로 치환오메가-카르복시아릴 디페닐 우레아 |
| EP1797038B1 (en) * | 2004-09-29 | 2012-06-13 | Bayer Pharma Aktiengesellschaft | Thermodynamically stable form of bay 43-9006 tosylate |
| AR062927A1 (es) * | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| WO2008089389A2 (en) * | 2007-01-19 | 2008-07-24 | Bayer Healthcare Llc | Treatment of cancers with acquired resistance to kit inhibitors |
| JP2011525503A (ja) * | 2008-06-25 | 2011-09-22 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 心不全を処置するためのジアリールウレア |
| CA2796744A1 (en) * | 2010-04-17 | 2011-10-20 | Bayer Healthcare Llc | Synthetic metabolites of fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| AU2011310532B2 (en) | 2010-10-01 | 2016-01-14 | Bayer Intellectual Property Gmbh | Substituted N-(2-arylamino)aryl sulfonamide-containing combinations |
| US20140127295A1 (en) * | 2011-03-14 | 2014-05-08 | Cellworks Group, Inc | Compositions, process of preparation of said compositions and method of treating inflammatory diseases |
| EP3082428A4 (en) | 2013-12-09 | 2017-08-02 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1478358B1 (en) * | 2002-02-11 | 2013-07-03 | Bayer HealthCare LLC | Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis |
| ATE386528T1 (de) * | 2002-04-10 | 2008-03-15 | Univ Virginia Commonwealth | Kombination von glivec (sti571) mit einem cyclinabhängigen kinaseinhibitoren, ins besonders flavopiridol, zur behandlung von krebs |
| ES2288694T3 (es) * | 2003-05-20 | 2008-01-16 | Bayer Pharmaceuticals Corporation | Diaril ureas para enfermedades mediadas por el receptor del factor de crecimiento derivado de plaquetas. |
| KR101139557B1 (ko) * | 2003-07-23 | 2012-04-30 | 바이엘 파마슈티칼스 코포레이션 | 질환 및 상태의 치료 및 예방을 위한 플루오로 치환오메가-카르복시아릴 디페닐 우레아 |
| EP1850852A4 (en) * | 2005-02-22 | 2009-11-18 | Cedars Sinai Medical Center | USE OF SILDENAFIL, VARDENAFIL AND OTHER 5-PHOSPHODIESTERASE INHIBITORS TO INCREASE THE PERMEABILITY OF THE ABNORMAL BLOOD-BRAIN DISEASE |
-
2006
- 2006-10-30 EP EP06818314A patent/EP1948170A1/en not_active Withdrawn
- 2006-10-30 BR BRPI0618522-3A patent/BRPI0618522A2/pt not_active IP Right Cessation
- 2006-10-30 US US12/084,662 patent/US20100035888A1/en not_active Abandoned
- 2006-10-30 JP JP2008539299A patent/JP5084736B2/ja not_active Expired - Fee Related
- 2006-10-30 CA CA002628849A patent/CA2628849A1/en not_active Abandoned
- 2006-10-30 KR KR1020087013800A patent/KR20080067000A/ko not_active Withdrawn
- 2006-10-30 AU AU2006312714A patent/AU2006312714A1/en not_active Abandoned
- 2006-10-30 WO PCT/EP2006/010406 patent/WO2007054216A1/en not_active Ceased
- 2006-10-31 AR ARP060104767A patent/AR057849A1/es not_active Application Discontinuation
- 2006-11-07 UY UY29903A patent/UY29903A1/es not_active Application Discontinuation
- 2006-11-09 PE PE2006001406A patent/PE20070806A1/es not_active Application Discontinuation
- 2006-11-09 TW TW095141431A patent/TW200733961A/zh unknown
-
2008
- 2008-05-01 IL IL191178A patent/IL191178A0/en unknown
- 2008-05-06 SV SV2008002900A patent/SV2009002900A/es not_active Application Discontinuation
- 2008-05-06 CR CR9953A patent/CR9953A/es not_active Application Discontinuation
- 2008-05-06 GT GT200800058A patent/GT200800058A/es unknown
- 2008-05-07 EC EC2008008430A patent/ECSP088430A/es unknown
- 2008-06-04 NO NO20082498A patent/NO20082498L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200733961A (en) | 2007-09-16 |
| JP5084736B2 (ja) | 2012-11-28 |
| NO20082498L (no) | 2008-08-07 |
| IL191178A0 (en) | 2009-08-03 |
| CA2628849A1 (en) | 2007-05-18 |
| UY29903A1 (es) | 2007-06-29 |
| ECSP088430A (es) | 2008-07-30 |
| EP1948170A1 (en) | 2008-07-30 |
| CR9953A (es) | 2008-10-08 |
| KR20080067000A (ko) | 2008-07-17 |
| WO2007054216A1 (en) | 2007-05-18 |
| BRPI0618522A2 (pt) | 2011-09-06 |
| US20100035888A1 (en) | 2010-02-11 |
| GT200800058A (es) | 2010-02-23 |
| PE20070806A1 (es) | 2007-09-29 |
| SV2009002900A (es) | 2009-04-28 |
| AU2006312714A1 (en) | 2007-05-18 |
| JP2009514910A (ja) | 2009-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR057849A1 (es) | Dialurrea para el tratamiento de hipertension pulmonar | |
| DOP2006000170A (es) | Nuevos derivados de espirocromanona | |
| CO2023001407A2 (es) | Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos | |
| PE20120626A1 (es) | Composiciones farmaceuticas que comprende nilotinib | |
| NO20072978L (no) | Nye betuinderivater, preparat derav og anvendelse derav | |
| MA32135B1 (fr) | Inhibiteurs de pim kinase et leurs procedes d'utilisation | |
| MX2009001659A (es) | Compuestos de 2,5-dihidroxibenceno para el tratamiento de rosacea. | |
| BRPI0513433A (pt) | derivados de hidantoìna para o tratamento de distúrbios inflamatórios | |
| ECSP034603A (es) | Combinaciones sinergicas que comprenden un inhibidor de renina para enfermedades cardiovasculares | |
| UY31084A1 (es) | Compuestos de azaindol para la inhibicion de b-secretasa | |
| HRP20050663A2 (en) | Malonamide derivatives as gamma-secretase inhibitors | |
| BRPI0612072A2 (pt) | inibidores da aspartil protease | |
| AR068947A1 (es) | Inhibidor de la proteina activadora de la 5- lipoxigenasa (flap), composiciones farmaceuticas, sales y solvatos | |
| PE20151666A1 (es) | Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep | |
| ATE554084T1 (de) | N-hydroxyacrylamidverbindungen | |
| AR119318A1 (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 | |
| DE602006011752D1 (de) | Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate | |
| NO20091254L (no) | Terapeutiske sammensetninger | |
| DOP2022000054A (es) | Inhibidor de irak y método de preparación para el mismo y uso del mismo | |
| MX2023013683A (es) | Compuestos de isoxazolilo fusionados como inhibidores de lisina acetiltransferasa 6a (kat6a). | |
| ECSP055745A (es) | Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona | |
| PA8542901A1 (es) | Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple | |
| JP2009514910A5 (es) | ||
| JOP20170197B1 (ar) | الصيغة الجديدة التي تشتمل على مشتق بنزيميدازول | |
| DOP2005000039A (es) | Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |